Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug
PTI, Dec 1, 2020, 1:50 PM IST
New Delhi: Drug major Glenmark Pharma on Tuesday said it has received tentative approval from the US health regulator for Axitinib tablets, used in the treatment of kidney cancer. The tentatively approved product is the generic version of Inlyta tablets of PF Prism CV.
Glenmark Pharmaceuticals Inc, USA has received tentative approval by the United States Food & Drug Administration (USFDA) for Axitinib tablets in the strength of 1 mg and 5 mg, the company said in a regulatory filing.
Quoting IQVIA sales data for the 12 months ending October 2020, Glenmark Pharma said the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately USD 518.8 million.
Glenmark’s current portfolio consists of 166 products authorised for distribution in the US market and 45 ANDA’s pending approval with the USFDA.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Turn back time? Study hints at way to halt decline as we age
Health-tech, cloud to see major growth in India in 2021: Report
IISc’s Centre for Networking Intelligence gets new state- of-the-art networking lab
Turning off cameras during web call helps reduce carbon footprint: study
Climate change may change rainfall patterns in south India, intensify floods: Study
MUST WATCH
Harassment on city bus: Victim slaps ‘arrested’ molestor in front of police
Bricks Made From Used Plastic Water Bottles | Complete Information
Vijay Prakash | Self Charging Electric Bike Made by Autorickshaw driver
Service on Wheels: Government services at one’s doorstep
Homemade Toy Electric Car using Waste Materials
Latest Additions
5 dead in fire at Covid-19 vaccine maker Serum Institute’s Manjari plant
India to face higher security challenges in line with rising stature, influence, says Army Chief Naravane
Commerce ministry recommends anti-dumping duty on Chinese chemical used in dye, Pharma industries
Hawk-i test fires smart anti-airfield weapon capable of destroying enemy assets from 100 km
Elected representatives above 50 yrs likely to be vaccinated against COVID-19 in next round